Cord-Blood Transplantation in Patients with Minimal Residual Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study.International journal of hematology · 2021
   Trial
2. Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis.Bone marrow transplantation · 2020
   Trial
3. A Modified Intensive Strategy to Prevent Cytomegalovirus Disease in Seropositive Umbilical Cord Blood Transplantation Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
   Trial
4. Ex Vivo Expansion and Homing of Human Cord Blood Hematopoietic Stem Cells.Advances in experimental medicine and biology · 2023
   Article
5. A new beginning: can omidubicel emerge as the next, viable alternative donor source?Therapeutic advances in hematology · 2023
   Review
6. Naive T Cells in Graft Versus Host Disease and Graft Versus Leukemia: Innocent or Guilty?Frontiers in immunology · 2022
   Review
7. Controversies and expectations for the prevention of GVHD: A biological and clinical perspective.Frontiers in immunology · 2022
   Review
8. Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions.Frontiers in pediatrics · 2021
   Review
9. Factors Predicting the Presence of Maternal Cells in Cord Blood and Associated Changes in Immune Cell Composition.Frontiers in immunology · 2021
   Observational
10. Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Article
11. Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation.PLoS computational biology · 2019
    Article
12. Recombinant Pregnancy-Specific Glycoprotein 1 Has a Protective Role in a Murine Model of Acute Graft-versus-Host Disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Article
13. Is it time to re-think a sustainable banking model for the Italian Cord Blood Network?Blood transfusion = Trasfusione del sangue · 2018
    Article

Corrections and comments

• Comment on
  Cord-Blood Transplantation in Patients with Minimal Residual Disease.2016
• Comment on
  Cord-Blood Transplantation in Patients with Minimal Residual Disease.2016
• Comment on
  Cord-Blood Transplantation in Patients with Minimal Residual Disease.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as